8-KLeadership Changes

BIOGEN INC. 8-K Report, Executive Changes (Jun 26, 2018)

Filed June 26, 2018For Securities:BIIB

Summary

Biogen Inc. announced a significant leadership change in its finance department via an 8-K filing on June 26, 2018. Gregory F. Covino will be stepping down as Vice President, Finance and Chief Accounting Officer, effective July 11, 2018. This transition marks a shift in key financial oversight for the company. In response to Mr. Covino's departure, Biogen has appointed Jeffrey D. Capello, currently the Executive Vice President and Chief Financial Officer, to also assume the role of Chief Accounting Officer, effective the same date. This consolidation of roles suggests a strategic move to streamline financial leadership. Investors should note Mr. Capello's extensive experience across various senior financial positions within the healthcare and technology sectors, including previous roles at Boston Scientific and PerkinElmer, as he takes on these dual responsibilities.

Key Highlights

  • 1Gregory F. Covino is stepping down as Vice President, Finance and Chief Accounting Officer of Biogen Inc. effective July 11, 2018.
  • 2Jeffrey D. Capello, Biogen's EVP and CFO, will assume the additional role of Chief Accounting Officer, effective July 11, 2018.
  • 3This appointment consolidates key financial leadership roles under Mr. Capello.
  • 4Mr. Capello brings a wealth of experience from previous senior financial roles at companies like Boston Scientific, PerkinElmer, and Ortho-Clinical Diagnostics.
  • 5Mr. Capello's background includes extensive experience in global finance, business development, and accounting.
  • 6The filing confirms Biogen is not an Emerging Growth Company, indicating it does not elect to use extended transition periods for accounting standards.

Frequently Asked Questions

The filing indicates that Jeffrey D. Capello, the current Executive Vice President and Chief Financial Officer, will assume the duties of Chief Accounting Officer. This suggests a strategic decision by Biogen to consolidate key financial leadership responsibilities under one executive, potentially for efficiency and streamlined oversight.

Jeffrey D. Capello has a substantial background in finance. He has served as Biogen's EVP and CFO since December 2017. Prior to that, he held CFO positions at Beacon Health Options, founded Monomoy Advisors, and had significant roles at Ortho-Clinical Diagnostics, Boston Scientific Corporation (including Senior Vice President and Chief Accounting Officer), and PerkinElmer, Inc. (including CFO, Corporate Controller, Treasurer, and Chief Accounting Officer). He also has experience as a Partner at PricewaterhouseCoopers LLP.

The departure of a Chief Accounting Officer can sometimes raise concerns about financial reporting continuity. However, Biogen's appointment of its experienced CFO, Jeffrey D. Capello, to also hold the Chief Accounting Officer title may mitigate these concerns. Mr. Capello's extensive experience in accounting and finance roles across several major companies suggests a strong ability to manage these responsibilities effectively.

The filing explicitly states that Biogen is NOT an emerging growth company (indicated by unchecked boxes). This means Biogen is not taking advantage of the extended transition period for complying with new or revised financial accounting standards available to emerging growth companies. For investors, this implies Biogen adheres to the latest accounting standards without delay, which can be seen as a sign of maturity and commitment to timely financial reporting.